首页> 美国卫生研究院文献>other >Differential impact of minimal residual disease negativity according to salvage status in patients with relapsed/refractory B cell acute lymphoblastic leukemia

【2h】

Differential impact of minimal residual disease negativity according to salvage status in patients with relapsed/refractory B cell acute lymphoblastic leukemia

机译：根据抢救状况将最小残留疾病阴性率对复发/难治性B细胞急性淋巴细胞白血病患者的不同影响

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundMinimal residual disease (MRD) assessment predicts survival in newly diagnosed acute lymphoblastic leukemia (ALL). Its significance in relapsed/refractory ALL is less clear.

机译：背景最小残留疾病（MRD）评估可预测新诊断的急性淋巴细胞白血病（ALL）的存活率。其在复发/难治性ALL中的意义尚不清楚。

著录项

期刊名称 other
作者
Elias Jabbour; Nicholas J. Short; Jeffrey L. Jorgensen; Musa Yilmaz; Farhad Ravandi; Sa A. Wang; Deborah A. Thomas; Joseph Khoury; Richard E. Champlin; Issa Khouri; Partow Kebriaei; Susan M. O’Brien; Guillermo Garcia-Manero; Jorge E. Cortes; Koji Sasaki; Courtney D. Dinardo; Tapan M. Kadia; Nitin Jain; Marina Konopleva; Rebecca Garris; Hagop Kantarjian;
展开▼
作者单位

展开▼
年(卷),期 -1(123),2
年度 -1
页码 294–302
总页数 16
原文格式 PDF
正文语种
中图分类
关键词
Acute lymphoblastic leukemia minimal residual disease relapsed refractory inotuzumab blinatumomab;

机译：急性淋巴细胞白血病;残留病极少;复发;难治;inotozumab;blinatumomab;

相似文献

外文文献
中文文献
专利

1. Differential Impact of Minimal Residual Disease Negativity According to the Salvage Status in Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia [J] . Jabbour Elias, Short Nicholas J., Jorgensen Jeffrey L., Cancer: A Journal of the American Cancer Society . 2017 ,第2期

机译：根据复发/难治性B细胞急性淋巴细胞白血病患者的挽救状态，最小残留疾病消极性的差异影响
2. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial [J] . Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis . 2020 ,第期

机译：在III in Ino-Vate试验中，在Inotuzumab ozogamicin治疗复发/难治性急性淋巴细胞白血病患者中的影响
3. Prognostic Impact of Full Hematologic Recovery and Achievement of Measurable Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) After First Salvage Therapy [J] . Rafei Hind, Ravandi Farhad, Hwang Hyunsoo, Clinical lymphoma, myeloma & leukemia . 2019 ,第Suppla1期

机译：在首次救助治疗后复发或难治性（R / R）急性髓性白血病（AML）患者的全血液学回收和可测量残余疾病（MRD）消极性的预后影响
4. Discrimination of minimal residual disease in acute lymphoblastic leukemia by using single-beam acoustic tweezer [C] . Hsiao-Cliuan Liu, Hye Na Kim, Enzi Jiang, IEEE International Ultrasonics Symposium . 2017

机译：用单束声镊鉴别急性淋巴细胞白血病的最小残留病
5. Volatile Biomarkers from Cultured Human Immune Cells, Cultured Human Acute Lymphoblastic Leukemia Cells and the Exhaled Breath of Patients with Acute Myelogenous Leukemia [D] . Umber, Brandon James 2012

机译：培养的人类免疫细胞，培养的人类急性淋巴细胞白血病细胞和急性粒细胞性白血病患者呼气中的挥发性生物标志物
6. Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy [O] . Prashant Ramesh Tembhare, Harshini Sriram, Twinkle Khanka, 2020

机译：流式细胞术评估新诊断的T细胞急性淋巴细胞白血病中CD38表达水平以及化疗对其在可测量的残留疾病难治性疾病和复发性疾病中的表达的影响：对抗CD38免疫疗法的意义
7. Allogeneic Hematopoietic Cell Transplantation (HCT) Yields Lower Relapse Rates but No Overall Survival Benefit for Adults with Acute Lymphoblastic Leukemia (ALL) in First Minimal Residual Disease (MRD)-Negative Remission [O] . Cassaday Ryan D., Potts D. Alan, Stevenson Philip A., 2015

机译：同种异体造血细胞移植（HCT）可使复发率降低，但对于首发最小残留病（MRD）-阴性缓解的急性淋巴细胞白血病（ALL）的成年人没有总体生存益处

Differential impact of minimal residual disease negativity according to salvage status in patients with relapsed/refractory B cell acute lymphoblastic leukemia

摘要

著录项

相似文献

相关主题

期刊订阅